Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno- and chemotherapy (PTIC).
Houtenbos I, Bracho F, Davenport V, Slack R, van de Ven C, Suen Y, Killen R, Shen V, Cairo MS. Houtenbos I, et al. Among authors: shen v. Bone Marrow Transplant. 2001 Jan;27(2):145-53. doi: 10.1038/sj.bmt.1702750. Bone Marrow Transplant. 2001. PMID: 11281383 Clinical Trial.
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH. Cairo MS, et al. Among authors: shen v. Br J Haematol. 2005 Jan;128(1):49-58. doi: 10.1111/j.1365-2141.2004.05281.x. Br J Haematol. 2005. PMID: 15606549 Free article. Clinical Trial.
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH. Cairo MS, et al. Among authors: shen v. J Pediatr Hematol Oncol. 2001 Jan;23(1):30-8. doi: 10.1097/00043426-200101000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11196267 Clinical Trial.
Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, Lenarsky C, Weinthal J, Hughes R, Cairo MS. Goldman SC, et al. Among authors: shen v. J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):300-5. doi: 10.1097/00043426-200106000-00013. J Pediatr Hematol Oncol. 2001. PMID: 11464987 Clinical Trial.
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Bracho F, Krailo MD, Shen V, Bergeron S, Davenport V, Liu-Mares W, Blazar BR, Panoskaltsis-Mortari A, van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. Bracho F, et al. Among authors: shen v. Clin Cancer Res. 2001 Jan;7(1):58-67. Clin Cancer Res. 2001. PMID: 11205919 Clinical Trial.
248 results